HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. (Q43047613)

12 November 2017

title

HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. (English)

1 reference

12 November 2017

1 reference

Manuel Romero-Gómez

1

1 reference

12 November 2017

María Francisca González-Escribano

2

1 reference

12 November 2017

Belén Torres

3

1 reference

12 November 2017

Natalia Barroso

4

1 reference

12 November 2017

Marco Antonio Montes-Cano

5

1 reference

12 November 2017

Diego Sánchez-Muñoz

6

1 reference

12 November 2017

Antonio Núñez-Roldan

7

1 reference

12 November 2017

José Aguilar-Reina

8

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

The American Journal of Gastroenterology

12 November 2017

published in

1 reference

12 November 2017

volume

98

1 reference

12 November 2017

issue

7

1 reference

12 November 2017

page(s)

1621-1626

1 reference

Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Flow cytometric analysis of peptide binding to major histocampatibility complex class I for hepatitis C virus core T-cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

MHC class II genes influence the susceptibility to chronic active hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Host genetic factors influence disease progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Discrimination of a single base change in a ribozyme using the gene for dihydrofolate reductase as a selective marker in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

HLA class II favors clearance of HCV infection and progression of the chronic liver damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

Ca2+ and rho signaling pathways: two paths to hepatic stellate cell contraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07537.X

10.1111/J.1572-0241.2003.07537.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference